Cliff J M, Milton-Thompson G J
Gut. 1970 Feb;11(2):167-70. doi: 10.1136/gut.11.2.167.
A controlled trial of carbenoxolone sodium positioned-release capsules (Duogastrone) was carried out on a randomized series of 100 unselected male Service personnel with symptoms of active duodenal ulceration and supporting radiological evidence. Fifty-seven patients completed the trial, 29 in the carbenoxolone group and 28 in the control group. The carbenoxolone group was given capsules containing 50 mg carbenoxolone four times a day for 12 weeks while the controls received a capsule identical in every respect except that it did not contain carbenoxolone. All patients were assessed at fortnightly intervals and had clinical and radiological reassessments three and six months after commencing treatment. Review at three months and at six months revealed a slight but clinically insignificant trend in favour of the carbenoxolone group. As a corollary to this controlled trial, those patients (38 in all) who did not have an early remission of symptoms were removed from the trial and placed on capsules known to contain carbenoxolone. Subsequently these patients did not show an advantage for carbenoxolone.
对100名出现活动性十二指肠溃疡症状且有相应放射学证据的未经过挑选的男性军人进行了一项关于甘珀酸钠定位释放胶囊（商品名：胃溃宁）的对照试验。100名患者随机分组，57名患者完成了试验，其中甘珀酸钠组29人，对照组28人。甘珀酸钠组患者每日服用4次含50毫克甘珀酸钠的胶囊，持续12周，而对照组服用的胶囊在各方面均与试验组相同，但不含甘珀酸钠。所有患者每两周接受一次评估，并在开始治疗后的3个月和6个月进行临床和放射学重新评估。3个月和6个月时的复查显示，有轻微但临床上无显著意义的趋势表明甘珀酸钠组更具优势。作为这项对照试验的一个推论，那些（总共38名）症状未早期缓解的患者被排除在试验之外，并给予已知含有甘珀酸钠的胶囊。随后，这些患者并未显示出甘珀酸钠的优势。
